BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 20808167)

  • 1. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
    Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
    J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract]   [Full Text] [Related]  

  • 4. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases.
    Dhaille F; Viseux V; Caudron A; Dadban A; Tribout C; Boumier P; Clabaut A; Lok C
    Dermatology; 2010; 220(3):234-7. PubMed ID: 20185892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
    Toussirot E; Berthelot JM; Pertuiset E; Bouvard B; Gaudin P; Wendling D; le Noach J; Lohse A; Lecuyer E; Cri L
    J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
    Ang HT; Helfgott S
    J Rheumatol; 2003 Nov; 30(11):2315-8. PubMed ID: 14677170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.
    Toussirot E; Pertuiset E; Kantelip B; Wendling D
    Clin Exp Rheumatol; 2008; 26(3):471-5. PubMed ID: 18578973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
    Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
    Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of pulmonary and cardiac sarcoidosis during etanercept therapy.
    Miyagi R; Ideguchi H; Soga T; Yamakawa Y; Otsuki H; Niino H; Shiina T; Ueda A; Ishigatsubo Y
    Int J Rheum Dis; 2014 Sep; 17(7):810-2. PubMed ID: 24460777
    [No Abstract]   [Full Text] [Related]  

  • 11. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
    Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.
    Verschueren K; Van Essche E; Verschueren P; Taelman V; Westhovens R
    Clin Rheumatol; 2007 Nov; 26(11):1969-71. PubMed ID: 17340045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
    Wallenius M; Rødevand E; Skomsvoll JF
    Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1664-6. PubMed ID: 15976836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
    Exarchou SA; Voulgari PV; Markatseli TE; Zioga A; Drosos AA
    Scand J Rheumatol; 2009; 38(5):328-31. PubMed ID: 19579151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
    Gottlieb GS; Lesser CF; Holmes KK; Wald A
    Clin Infect Dis; 2003 Sep; 37(6):838-40. PubMed ID: 12955647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF-alpha-induced systemic lupus syndrome.
    Debandt M; Vittecoq O; Descamps V; Le Loët X; Meyer O
    Clin Rheumatol; 2003 Feb; 22(1):56-61. PubMed ID: 12605321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.
    Gifre L; Ruiz-Esquide V; Xaubet A; Gómez-Puerta JA; Hernández MV; Sanmartí R
    Arch Bronconeumol; 2011 Apr; 47(4):208-12. PubMed ID: 20638761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
    Antoni C; Manger B
    Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.